pantoprazole has been researched along with Anxiety in 2 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asian patients with GERD symptoms (N = 209) received pantoprazole 40 mg daily for 8 weeks in a multinational, prospective, open-label study." | 2.79 | Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients. ( Choi, KD; Choi, MG; Goh, KL; Hsieh, TY; Jung, HY; Lien, HC; Menon, J; Mesenas, S; Park, H; Sheu, BS; Wu, JC, 2014) |
| "Management of patients with gastro-oesophageal reflux disease (GORD) can be assisted by information predicting the likely response to proton pump inhibitor (PPI) treatment." | 2.76 | Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. ( Heading, RC; Mönnikes, H; Schmitt, H; Tholen, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, KL | 1 |
| Choi, KD | 1 |
| Choi, MG | 1 |
| Hsieh, TY | 1 |
| Jung, HY | 1 |
| Lien, HC | 1 |
| Menon, J | 1 |
| Mesenas, S | 1 |
| Park, H | 1 |
| Sheu, BS | 1 |
| Wu, JC | 1 |
| Heading, RC | 1 |
| Mönnikes, H | 1 |
| Tholen, A | 1 |
| Schmitt, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks[NCT00312806] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pantoprazole and Anxiety
| Article | Year |
|---|---|
Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anxiety; Asian People; Depression; Female; Gastroeso | 2014 |
Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anxiety; Body Mass Index; Female; Gastroesophageal R | 2011 |